These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36342722)

  • 1. High-risk Therapeutic Devices Approved by the US Food and Drug Administration for Use in Children and Adolescents From 2016 to 2021.
    Pathak K; Narang C; Hwang TJ; Espinoza JC; Bourgeois FT
    JAMA Pediatr; 2023 Jan; 177(1):98-100. PubMed ID: 36342722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postmarketing trials and pediatric device approvals.
    Hwang TJ; Kesselheim AS; Bourgeois FT
    Pediatrics; 2014 May; 133(5):e1197-202. PubMed ID: 24733871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. US Food and Drug Administration-Mandated Postmarketing Studies for High-risk Cardiovascular Devices Approved 2015-2019.
    Hidano D; Dhruva SS; Redberg RF
    JAMA Intern Med; 2022 May; 182(5):556-558. PubMed ID: 35286367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.
    Skydel JJ; Zhang AD; Dhruva SS; Ross JS; Wallach JD
    Clin Trials; 2021 Aug; 18(4):488-499. PubMed ID: 33863236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Devices, drugs, and the Food and Drug Administration: increasing implications for ischemic stroke.
    Furlan AJ; Fisher M
    Stroke; 2005 Feb; 36(2):398-9. PubMed ID: 15637320
    [No Abstract]   [Full Text] [Related]  

  • 6. Postmarket Clinical Evidence for High-Risk Therapeutic Medical Devices Receiving Food and Drug Administration Premarket Approval in 2010 and 2011.
    Rathi VK; Krumholz HM; Masoudi FA; Ross JS
    JAMA Netw Open; 2020 Aug; 3(8):e2014496. PubMed ID: 32857145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Evidence Supporting US Food and Drug Administration Clearance of Novel Therapeutic Devices via the De Novo Pathway Between 2011 and 2019.
    Johnston JL; Dhruva SS; Ross JS; Rathi VK
    JAMA Intern Med; 2020 Dec; 180(12):1701-1703. PubMed ID: 33044513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020.
    Moneer O; Lee CC; Avorn J; Kesselheim AS
    JAMA Netw Open; 2021 Apr; 4(4):e218530. PubMed ID: 33929526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Obstetric and Gynecologic Food and Drug Administration Device Approvals and Recalls.
    Galhotra S; Maurice J
    J Minim Invasive Gynecol; 2018; 25(7):1281-1288. PubMed ID: 29653261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Legal overprotection.
    Friedman JH
    Med Health R I; 2004 Oct; 87(10):294. PubMed ID: 15559378
    [No Abstract]   [Full Text] [Related]  

  • 11. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
    Skydel JJ; Luxkaranayagam AT; Dhruva SS; Ross JS; Wallach JD
    JAMA Netw Open; 2019 May; 2(5):e193410. PubMed ID: 31074812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.
    Shepshelovich D; Tibau A; Goldvaser H; Ocana A; Seruga B; Amir E
    Mayo Clin Proc; 2019 Jan; 94(1):74-83. PubMed ID: 30611457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011.
    Rathi VK; Krumholz HM; Masoudi FA; Ross JS
    JAMA; 2015 Aug; 314(6):604-12. PubMed ID: 26262798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Devices and the food and drug administration.
    Phillips SJ; Phillips RS
    Artif Organs; 2005 May; 29(5):363-5. PubMed ID: 15854210
    [No Abstract]   [Full Text] [Related]  

  • 15. Off-label use of medical devices in radiology: regulatory standards and recent developments.
    Smith JJ
    J Am Coll Radiol; 2010; 7(2):115-9. PubMed ID: 20142085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical device postapproval safety monitoring: where does the United States stand?
    Rajan PV; Kramer DB; Kesselheim AS
    Circ Cardiovasc Qual Outcomes; 2015 Jan; 8(1):124-31. PubMed ID: 25563662
    [No Abstract]   [Full Text] [Related]  

  • 17. US Congress considers new tracking system for medical devices after excessive recalls.
    Epstein K
    BMJ; 2012 Apr; 344():e2915. PubMed ID: 22529316
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceuticals and medical devices: medical devices.
    ; Berry MD
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-38. PubMed ID: 22403842
    [No Abstract]   [Full Text] [Related]  

  • 19. Medical device regulation: an introduction for the practicing physician.
    Maisel WH
    Ann Intern Med; 2004 Feb; 140(4):296-302. PubMed ID: 14970153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. User fees and beyond--the FDA Safety and Innovation Act of 2012.
    Kramer DB; Kesselheim AS
    N Engl J Med; 2012 Oct; 367(14):1277-9. PubMed ID: 23034017
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.